Tobramycin Inhalation Powder: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
- 734 Downloads
Inhaled tobramycin, an aminoglycoside antibacterial, has been in widespread use in the form of a nebulized solution against Pseudomonas aeruginosa for many years. More recently, tobramycin inhalation powder (TIP; TOBI® Podhaler™) was formulated using PulmoSphere™ technology for administration as a dry powder via the T-326 Inhaler. This technology enables the administration of an intrapulmonary drug dose that is similar to that achieved with nebulized tobramycin inhalation solution (TIS), but reduces the administration time for TIP to one-third of that for TIS. TIP is approved in several countries, including the EU and US, for use in cystic fibrosis (CF) patients aged ≥6 years with P. aeruginosa infection. In well designed clinical trials in CF patients, the antipseudomonal efficacy of intermittent twice-daily TIP 112 mg was greater than that of placebo in one trial (a second trial was unable to recruit sufficient patient numbers for meaningful analyses), and non-inferior to that of intermittent twice-daily nebulized TIS 300 mg/5 mL with regard to lung function and sputum density of P. aeruginosa. In addition, patients using TIP were more satisfied with their treatment than those using nebulized TIS, largely as a result of improved overall convenience. TIP is generally well tolerated, with a similar safety profile to that of TIS, except for a higher incidence of cough. In conclusion, TIP administered via the T-326 Inhaler is an effective antipseudomonal agent with non-inferior efficacy and generally similar tolerability to that of nebulized TIS in CF patients with chronic P. aeruginosa infection. Compared with nebulized TIS, TIP has a faster delivery and is more portable and convenient.
KeywordsCystic Fibrosis Tobramycin Cystic Fibrosis Patient Less Square Mean Improve Lung Function
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comments on the article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.
- 10.European Medicines Agency. TOBI Podhaler 28 mg inhalation powder, hard capsules. Summary of product characteristics. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002155/WC500110921.pdf. Accessed 17 Oct 2013.
- 11.Novartis Pharmaceuticals Corporation. TOBI PODHALER (Tobramycin Inhalation Powder). Full prescribing information. 2013. http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis.com/product/pi/pdf/tobipodhaler.pdf. Accessed 17 Oct 2013.
- 20.Haynes A, Ament B, Heng C, et al. In vitro aerosol delivery performance of tobramycin powder for inhalation (TOBI® PODHALER™) using inspiratory flow profiles from cystic fibrosis patients [abstract]. 27th Annual North American Cystic Fibrosis Conference; 17–19 Oct 2013; Salt Lake City.Google Scholar
- 22.Nasr S, Nick J, Ezzet N, et al. Reduced administration time for inhaled tobramycin in cystic fibrosis patients: results from the EAGER trial [abstract]. 27th Annual North American Cystic Fibrosis Conference; 17–19 Oct 2013; Salt Lake City.Google Scholar
- 27.Konstan MW, Flume PA, Wan R, et al. Long-term safety and efficacy of tobramycin inhalation powder in cystic fibrosis patients with P. aeruginosa: the EDIT trial and its two open-label extension studies [abstract]. 27th Annual North American Cystic Fibrosis Conference; 17–19 Oct 2013; Salt Lake City.Google Scholar
- 29.Regnault A, Bal MM, Kulich K, et al. Association of treatment satisfaction and compliance of cystic fibrosis (CF) patients using inhaled tobramycin treatment in the EAGER study. 34th European Cystic Fibrosis Conference; 8–11 June 2011, Hamburg.Google Scholar
- 31.Harrison MJ, McCarthy C, Fleming C, et al. Improved tolerability, adherence and reduced intravenous (IV) antibiotic usage in CF patients receiving inhaled versus nebulised antibiotic prophylaxis. A real world comparison of tobramycin inhaled powder (TIP) and tobramycin inhaled solution (TIS) [abstract no. 74]. J Cyst Fibros. 2013;12(Suppl):S67.CrossRefGoogle Scholar
- 32.Nash EF, Ahitan B, Brown CJ, et al. Comparison of pharmacy prescription refill frequency in CF adults before and after switching from tobramycin inhalation solution (TIS) to TOBI Podhaler: ‘real world’ evidence of improved adherence [abstract no. 68]. J Cyst Fibros. 2013;12(Suppl):S65.CrossRefGoogle Scholar
- 33.National Institute for Health and Clinical Excellence (NICE). Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis. 2013 Mar. http://guidance.nice.org.uk/TA276/Guidance/pdf/English. Accessed 19 Aug 2013.
- 34.Cystic Fibrosis Foundation. Patient registry: annual data report. 2011. http://www.cff.org/LivingWithCF/QualityImprovement/PatientRegistryReport/. Accessed 21 Aug 2013.
- 41.Mohamed AF, Reed Johnson FR, Balp MM, et al. Convenience and stated adherence for antibiotic treatment of cystic-fibrosis pseudomonas infections [abstract]. 27th Annual North American Cystic Fibrosis Conference; 17–19 Oct 2013; Salt Lake City.Google Scholar
- 43.Schelstraete P, Haerynck F, Van daele S, et al. Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colinized by P. aeruginosa. J Cyst Fibros. 2013;12:1–8.Google Scholar